1 |
Calin GA and Croce CM (2006). MicroRNA signatures in human cancers. Nat Rev Cancer, 6, 857-66.
DOI
ScienceOn
|
2 |
Chen J, Wang L, Matyunina LV, et al (2011). Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol, 121, 200-5.
DOI
ScienceOn
|
3 |
Chen Y, Zhang L and Hao Q (2013). Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation. Cancer Cell Int, 13, 86.
DOI
|
4 |
Di Leva G and Croce CM (2013). The role of microRNAs in the tumorigenesis of ovarian cancer. Front Oncol, 3, 153.
|
5 |
Faragalla H, Youssef YM, Scorilas A, et al (2012). The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn, 14, 385-92.
DOI
|
6 |
Flavin RJ, Smyth PC, Finn SP, et al (2008). Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol, 21, 676-84.
DOI
ScienceOn
|
7 |
He L, Hannon GJ (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet, 5, 522-31.
DOI
ScienceOn
|
8 |
Bendoraite A, Knouf EC, Garg KS, et al (2010). Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-toepithelial transition. Gynecol Oncol, 116, 117-25.
DOI
|
9 |
Hernando E (2007). microRNAs and cancer: role in tumorigenesis, patient classification and therapy. Clin Transl Oncol, 9, 155-60.
DOI
ScienceOn
|
10 |
Hu X, Macdonald DM, Huettner PC, et al (2009). A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol, 114, 457-64.
DOI
|
11 |
Iorio MV, Visone R, Di Leva G, et al (2007). MicroRNA signatures in human ovarian cancer. Cancer Res, 67, 8699-707.
DOI
ScienceOn
|
12 |
Calin GA, Ferracin M, Cimmino A, et al (2005). A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med, 353, 1793-801.
DOI
ScienceOn
|
13 |
Kumar MS, Erkeland SJ, Pester RE, et al (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA, 105, 3903-8.
DOI
|
14 |
Koberle V, Kronenberger B, Pleli T, et al (2013). Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer, 49, 3442-9.
DOI
|
15 |
Korpal M, Lee ES, Hu G and Kang Y (2008). The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem, 283, 14910-4.
DOI
ScienceOn
|
16 |
Kota J, Chivukula RR, O'Donnell KA, et al (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 137, 1005-17.
DOI
ScienceOn
|
17 |
Laios A, O'Toole S, Flavin R, et al (2008). Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer, 7, 35.
DOI
ScienceOn
|
18 |
Lu J, Getz G, Miska EA, et al (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834-8.
DOI
ScienceOn
|
19 |
Landen CN, Jr., Birrer MJ and Sood AK (2008). Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol, 26, 995-1005.
DOI
ScienceOn
|
20 |
Leskela S, Leandro-Garcia LJ, Mendiola M, et al (2011). The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer, 18, 85-95.
|
21 |
Li Z, Lu J, Sun M, et al (2008). Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA, 105, 15535-40.
DOI
|
22 |
Nam EJ, Yoon H, Kim SW, et al (2008). MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res, 14, 2690-5.
DOI
ScienceOn
|
23 |
Mateescu B, Batista L, Cardon M, et al (2011). miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med, 17, 1627-35.
DOI
|
24 |
Mo MH, Chen L, Fu Y, et al (2012). Cell-free circulating miRNA biomarkers in cancer. J Cancer, 3, 432-48.
DOI
|
25 |
Mostert B, Sieuwerts AM, Martens JW and Sleijfer S (2011). Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev Mol Diagn, 11, 259-75.
|
26 |
Resnick KE, Alder H, Hagan JP, et al (2009). The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol, 112, 55-9.
DOI
ScienceOn
|
27 |
Shell S, Park SM, Radjabi AR, et al (2007). Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA, 104, 11400-5.
DOI
ScienceOn
|
28 |
Tavazoie SF, Alarcon C, Oskarsson T, et al (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451, 147-52.
DOI
ScienceOn
|
29 |
Shen J, Ambrosone CB, DiCioccio RA, et al (2008). A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis, 29, 1963-6.
DOI
ScienceOn
|
30 |
Skaftnesmo KO, Prestegarden L, Micklem DR and Lorens JB (2007). MicroRNAs in tumorigenesis. Curr Pharm Biotechnol, 8, 320-5.
DOI
ScienceOn
|
31 |
Yan LX, Huang XF, Shao Q, et al (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14, 2348-60.
DOI
ScienceOn
|
32 |
Tang Z, Ow GS, Thiery JP, et al (2013). Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. Int J Cancer, 134, 306-18.
|
33 |
Taylor DD, Gercel-Taylor C (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol, 110, 13-21.
DOI
ScienceOn
|
34 |
Trang P, Medina PP, Wiggins JF, et al (2010). Regression of murine lung tumors by the let-7 microRNA. Oncogene, 29, 1580-7.
DOI
|
35 |
Yanaihara N, Caplen N, Bowman E, et al (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9, 189-98.
DOI
ScienceOn
|
36 |
Yang H, Kong W, He L, et al (2008). MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res, 68, 425-33.
DOI
ScienceOn
|
37 |
Yang N, Kaur S, Volinia S, et al (2008). MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res, 68, 10307-14.
DOI
ScienceOn
|
38 |
Zhang L, Volinia S, Bonome T, et al (2008). Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA, 105, 7004-9.
DOI
|
39 |
Wong AS and Auersperg N (2003). Ovarian surface epithelium: family history and early events in ovarian cancer. Reprod Biol Endocrinol, 1, 70.
DOI
|